Aspirin prophylaxis in patients at low risk for cardiovascular disease: A systematic review of all-cause mortality

Journal of Family Practice

Volumn 51, Issue 8, 2002, Pages 700-704

  Boltri, John M ^a   Akerson, Mark R ^a   Vogel, Robert L ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Low risk patient; Mortality; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HUMAN; MEDLINE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROPHYLAXIS; STANDARD;

ASPIRIN; CARDIOVASCULAR DISEASES; HUMANS; RISK ASSESSMENT;

EID: 0036330354     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Aspirin as a therapeutic agent in cardiovascular disease
2. Impaired platelet/connective-tissue reaction in man after aspirin ingestion
3. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin
4. One year after CAPRIE, IST, and ESPS 2
5. Prevention of cardiovascular disease: Risks and benefits of aspirin
6. The European Stroke Prevention Study: Results according to sex
7. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
8. Collaborative overview of randomised trials of anti-platelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
9. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
10. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events
11. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
12. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
13. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease
14. Primary Prevention of CHD: Nine ways to reduce risk
15. Assessing the quality of reports of randomized clinical trials: Is binding necessary?
16. Final report on the aspirin component of the ongoing Physicians' Health Study
17. Randomized trial of prophylactic daily aspirin in British male doctors
18. A prospective study of aspirin use and primary prevention of cardiovascular disease in women
19. The Pace Pilot Study: 12-month results and implications for future primary prevention trials in the elderly
20. Baseline characteristics of participants in the Physicians Health Study: A randomized trial of aspirin and beta-carotene in U.S. physicians
21. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
22. Aspirin use and reduced risk of fatal colon cancer
23. Aspirin in the primary prevention of cardiovascular disease
24. Antiplatelet therapy and risk of stroke
25. Prospective study of aspirin use and risk of stroke in women
26. Aspirin use and incident stroke in the cardiovascular study
27. Aspirin use and chronic diseases: A cohort study of the elderly
28. Adverse effects of low-dose aspirin in a healthy population